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Rhabdomyosarcoma (RMS) is a family of
soft tissue tumors that generally occur in
the pediatric population. The develop-
mental origin of RMS is unclear.
However, RMS cells express a number
of skeletal muscle markers such as
desmin, sarcomeric actin, sarcomeric
myosin heavy chain, and muscle-specific
transcription factor MyoD. In addition,
cytoplasmic striations, a sarcomeric
muscle-specific characteristic, can be
detected in RMS cells. These observa-
tions suggest myogenic cell origin of
RMS (Merlino and Helman, 1999).
RMS can be categorized as two dif-
ferent types: embryonal and alveolar
RMS. Embryonal RMS is characterized
by loss of heterozygosity (LOH) at the
11p15 region where it is maternally
imprinted in normal tissue and locates a
number of imprinted genes such as H19,
insulin-like growth factor 2 (IGF2), and
p57KIP2. LOH at these loci results in tran-
scriptional activation from both maternal
and paternal alleles and increases
expressions of the imprinted genes such
as IGF2 observed in RMS. Alveolar RMS
tends to occur in the older age group. 90%
of alveolar RMS carry a characteristic
chromosomal translocation of DNA bind-
ing domain of the Pax3 or Pax7 gene to
the transactivation domain of FKHR gene
at t(2;13)(q35;q14) or t(1;13)(p36;q14),
respectively (Merlino and Helman, 1999).
Pax3 and Pax7, a member of the Paired
box transcription family, are involved in
skeletal muscle development. Gene
mutant mice demonstrate that Pax3 is
essential for embryonic skeletal muscle
development by regulating gene expres-
sion of c-met, a hepatocyte growth fac-
tor/scatter factor (HGF/SF) receptor,
required for myogenic cell migration
(Buckingham, 2001). In contrast, Pax7 is
required for specification of muscle satel-
lite cells and myogenic stem cells and
essential for postnatal muscle growth and
regeneration (Seale et al., 2000). FKHR is
a member of the forkhead/HNF-3 tran-
scription factor family. The chimeric pro-
tein of Pax3-FKHR is a more potent
transcriptional activator than wild-type
Pax3. Ectopic expression of the chimeric
gene converts fibroblasts to myogenic
cells by activation of a number of muscle-
specific genes (Khan et al., 1999). These
observations indicate that overexpression
of growth factors such as IGF2 or activa-
tion of Pax genes results in RMS.
RMS is also generated in Li-
Fraumeni syndrome associated with
Trp53 germline mutations. In addition,
some sporadic cases of RMS involved
Trp53 germline mutations (Merlino and
Helman, 1999). Trp53, a transcription
factor, is a tumor suppressor gene prod-
uct involved in cell apoptosis, cell cycle
withdraw, differentiation, and cellular
senescence (Kirkwood, 2002). Trp53 is
activated by a number of cellular stress-
es such as DNA damages.The transcrip-
tional activity of Trp53 was first found in
skeletal muscle-specific gene muscle
creatine kinase (MCK) enhancer.
However, mice carrying null mutations in
both Trp53 alleles (Trp53−/−) seem to
exhibit normal skeletal muscle develop-
ment (White et al., 2002). Trp53−/− mice
increase tumor susceptibility in adult-
hood. The majority of tumors are lym-
phomas and RMS is very rare in these
mice. However, Trp53 heterozygotes
(Trp53+/−) develop mostly sarcomas and
19% of sarcomas are RMS. These
results suggest implication of Trp53 gene
in rhabdomyosarcomagenesis (Merlino
and Helman, 1999).
Here, Fleischmann et al. (2003)
described remarkable results in which
Trp53/Fos double knockout mice devel-
oped highly proliferative and invasive
rhabdomyosarcomas of the facial and
orbital regions, which is a similar location
as seen in human rhabdomyosarcoma
patients. Fos is a zinc finger transcription
factor consisting of AP-1 and regulates
various biological processes by transcrip-
tional activation of a number of target
genes downstream of signaling pathways
such as Protein Kinase C (PKC)
(Acquaviva et al., 2002). Fos−/− mice dis-
play osteopetrosis due to lack of
osteoclasts. Overexpression of Fos in
transgenic mice causes them to develop
chondrosarcoma and osteosarcoma. Fos
is also known to regulate apoptotic sig-
naling pathways. Fleischmann et al. gen-
erated Trp53/Fos compound mutant mice
(Trp53−/−;Fos−/−), and these mice initially
developed osteopetrosis similar to the
phenotype seen in Fos−/− mice. However,
Trp53−/−;Fos−/− mice started to develop
tumors of the facial and orbital regions at
10 weeks of age and the tumor pene-
trance was over 90% at 25 weeks. These
tumor cells with polygonal or elongated
shape expressed a cell cycle-associated
protein and a number of skeletal muscle
markers such as desmin and MyoD.
These characteristics are very similar to
human RMS. Cell lines isolated from the
RMS-like tumors expressed desmin and
MyoD. Differentiation condition such as
low serum induced myotube formation
of the Trp53−/−;Fos−/− RMS cells, in
which cytoplasmic cross-striations were
observed. Reexpression of Trp53 or Fos
in the Trp53−/−;Fos−/− RMS cells induced
apoptotic cell death. Interestingly, while
reexpression of Fos in the Trp53−/−;Fos−/−
RMS cells did not affect expression of
pro- or antiapoptotic genes such as Bcl-
2 family members and TNF-α/Fas path-
ways, Pax7 gene expression was
significantly reduced in these cells.
Reexpression of Fos in the Trp53−/−;Fos−/−
RMS cells also downregulated muscle-
specific gene expression and inhibited
myogenic differetiation. In addition, over-
expression of Fos in the primary
myoblasts also downregulated muscle-
specific gene expression, and Pax7 gene
expression was decreased to below the
detection limit. These results suggest the
interesting molecular mechanisms in
which Fos is the repressor for Pax7 gene
transcription and upregulation of Pax7
gene expression may result in increased
myoblast proliferation and prevent apop-
tosis. Finally, Fleischmann et al. conclud-
ed that Fos proto-oncogene possesses a
novel tumor-suppressive function and
provide an important mouse model for
human RMS.
The molecular mechanisms by
which Fos suppresses Pax7 gene tran-
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Rhabdomyosarcomagenesis—Novel pathway found
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Recent work presented in this issue of
Cancer Cell by Fleischmann et al. on gene knockout mice revealed a remarkable molecular pathway for rhabdomyosarco-
magenesis, in which Trp53/Fos double mutant mice developed RMS of the facial and orbital regions with high penetrance.
This finding may provide novel molecular mechanisms for Rhabdomyosarcomagenesis and therapeutic implications for
RMS patients.
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scription are still unknown. However,
upregulation of Pax gene expression is
clearly involved in rhabdomyosarcoma-
genesis. Pax3 is known to regulate c-met
gene transcription, overexpression of
which is occasionally seen in human
RMS. Overexpression of HGF/SF in
transgenic mice also caused RMS to
develop in 4% of mice (Merlino and
Helman, 1999). More recently, RMS is
frequently observed in mice carrying
overexpression of HGF/SF gene in an
Ink4a/Arf null background (Sharp et al.,
2002). These reports strongly suggest
that rhabdomyosaromagenesis impli-
cates Fos, Pax, c-met, and HGF/SF sig-
naling pathways. Although the origin of
RMS cells is assumed to be from myo-
genic cells such as satellite cells, recent
work demonstrates existence of novel
stem cells in muscle, which give rise to
myogenic cells during muscle regenera-
tion (Asakura et al., 2002; Polesskaya et
al., 2003).Therefore, the novel stem cells
in muscle such as side population (SP)
cells may be a developmental origin for
RMS cells, in which Fos/Pax/c-met path-
way is involved. In the near future, finding
the molecular mechanisms of Fos/Pax/c-
met pathway involved in rhabdomyosar-
comagenesis and the developmental
origin of RMS would not only facilitate
our understanding of the mechanisms of
rhabdomyosarcomagenesis but also
develop novel therapeutic applications
for human RMS patients.
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The accumulation of individual proteins
within eukaryotic cells reflects a tightly
controlled balance between protein syn-
thesis and degradation. Two major path-
ways for the degradation of proteins have
been described: cytosolic degradation by
the proteasome and autophagic degra-
dation of proteins and organelles within
the lysosome (Klionsky and Emr, 2000).
Considerable evidence suggests that the
proteasome is responsible for the regu-
lated degradation of short-lived proteins
involved in cell cycle control as well as
proteins that participate in stress
responses such as DNA damage-
induced cell cycle arrest or adaptation to
hypoxia. A number of examples linking
alterations in proteasomal protein degra-
dation to the pathogenesis of cancer
exist (Pagano and Benmaamar, 2003). In
contrast, alterations in autophagic degra-
dation of cellular proteins has not been
linked to the causation of cancer. Rather,
autophagy has been demonstrated to be
important in developmental/differentia-
tive remodeling of cells. Autophagy is
also required for the cellular adaptation
to nutrient deprivation and the elimina-
tion of damaged organelles (Figure 1;
Klionsky and Emr, 2000).
Regulation of autophagy
During autophagic degradation, cytoso-
lic proteins and/or organelles are first
sequestered within double membrane
vesicles, which are then fused to the
lysosome (Klionsky and Emr, 2000). The
vesicular contents are broken down by
pH-sensitive lysosomal hydrolases, and
the degradation products are recycled
for use in macromolecular synthesis
and/or bioenergetics. Relatively little is
known about how protein complexes and
organelles are specifically targeted for
degradation through autophagy.
However, much of the molecular machin-
ery required for autophagic vacuole for-
mation and fusion with the lysosome has
been identified through genetic screens
Defective autophagy leads to cancer
Cellular proteins are degraded within two distinct compartments: the proteasome and the lysosome. Alterations in protea-
somal degradation can contribute to carcinogenesis. In contrast, alterations in autophagic protein degradation through the
lysosome have not been linked to cancer. Now two reports demonstrate that the autophagic gene, Beclin 1, is a haploinsuf-
ficient tumor suppressor gene.These new data suggest that autophagic degradation provides an important mechanism to
prevent cellular transformation.
